Thank you, Mr. Chairman.
I agree with you that the length of the shutdown and the length of the supply issue are of concern. We have improved the utilization of the available supply in a number of short-term ways, and we have been able to keep patient volumes up better than we had originally envisaged. Clearly this is not sustainable over the long term. It is going to create problems for hospital staff, as they're working different processes and different patents.
I believe there are some opportunities. The approval of the molybdenum from the Australian reactor may provide us with some medium-term relief in molybdenum supply. We have to remember that reactors also make iodine-131, which is essential in the treatment of patients with thyroid cancer, which is my own area of expertise.